Atomic AI designs RNA-targeted small molecules and RNA-based therapeutics. Its platform features ATOM-1, a foundation model that predicts the three-dimensional structure of RNA. It targets biotechnology and pharmaceutical markets to enable treatments for previously undruggable diseases via RNA structure. The technology fuses machine learning with structural biology, employing deep learning models trained on chemical mapping data alongside in-house wet-lab assays. The company was founded by Raphael Townshend (CEO, Stanford CS PhD), with key executives Stephan Eismann (Founding Scientist and Head of Machine Learning), Brent Townshend (Head of ML Data Generation), Esta Kor (Head of Business Operations), and Manjunath Ramarao (Chief Scientific Officer, appointed October 2023). Atomic AI has raised $42M total, including a $35M Series A in January 2023 led by Playground Global with 8VC, Greylock, Factory HQ, and others, following a $7M seed round led by 8VC. It is headquartered in South San Francisco, CA.